Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

New insights into glaucoma and implications for drug therapy

July 15, 1997

Prostaglandins in early development at Allergan for glaucoma

July 4, 1997

BioSpecifics Technologies and Bausch & Lomb collaborate on glaucoma studies

June 27, 1997

Genistein prevents ischemic retinal degeneration in rats

June 25, 1997

Merck & Co. discloses muscarinic antagonists for myopia

June 20, 1997

Agents for glaucoma revealed by Merck & Co.

June 20, 1997

AEterna's IND for Neoretna approved in Canada

June 16, 1997

Retinal protein reduces need for standard drugs in uveitis

June 10, 1997

Oculex and Storz sign marketing agreement for ocular product

June 5, 1997

Monarch acquires ocular therapy from Glaxo Wellcome

May 30, 1997

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...